Iptacopan for idiopathic IC-MPGN with heavy protein in urine
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have idiopathic IC-MPGN, confirmed by a kidney biopsy done recently (within 12 months for adults; within 3 years for adolescents).
- You’ve been on the best tolerated “blood pressure kidney protection” medicines (ACE inhibitor or ARB) for at least 90 days before starting.
- Your urine protein level is high: first-morning urine test shows UPCR at least 1.0 g/g at two study timepoints.
- Your kidney filtration is not too low (eGFR or measured GFR is at least 30 at screening and at the next check).
- Before treatment, you must be up to date on vaccines against meningococcal and pneumococcal infections (and possibly Hib).
- You should not have recent serious infections or fever, and you should not be using certain immune/complement-blocking medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study looks at how well iptacopan works for people with C3G, a kidney disease. It aims to see if the treatment is safe and effective, and includes people who have already taken iptacopan.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
Hear when a new IC-MPGN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.